Observations on false positive reactions in the rapid NOW Filariasis card test

Beyond Tradition: Exploring Cutting-Edge Approaches for Accurate Diagnosis of Human Filariasis

Filariasis is recognised as a global public health threat, particularly in tropical and subtropical regions. It is caused by infection with a nematode parasite of the superfamily Filarioidea, including Wuchereria bancrofti, Brugia malayi, Onchocerca volvulus, and Onchocerca lupi. Three main types of filariasis have been classified: lymphatic filariasis, subcutaneous filariasis, and serous cavity filariasis. The symptoms exhibited by individuals afflicted with filariasis are diverse and contingent upon several variables, including the species of parasite, the host's health and immune response, and the stage of infection. While many classical parasitological techniques are considered indispensable tools for the diagnosis of parasitic infections in humans, alternative methods are being sought due to their limitations. Novel tests based on host-parasite interactions offer a rapid, simple, sensitive, and specific diagnostic tool in comparison to traditional parasitological methods. This article presents methods developed in the 21st century for the diagnosis of filariasis caused by invasion from W. bancrofti, B. malayi, O. volvulus, and O. lupi, as well as techniques that are currently in use. The development of modern diagnostic methods based on molecular biology constitutes a significant advancement in the fight against filariasis.

Evaluation of lymphatic filariasis in endemic area of Brazil where mass drug administration is not required

Mass drug administration (MDA) is the main counter-transmission strategy of the Global Programme to Eliminate Lymphatic Filariasis. In endemic countries, there are areas where MDA is not required. However, there is no standard approach in these areas, and studies are important to evaluate the epidemiological status. This study aimed to investigate lymphatic filariasis and strategies developed for its control in an area where MDA is not required. Together with the 2018 morbidity evaluation, a survey was conducted using point-of-care immunochromatographic test-AD12 tests for diagnostic screening in an area where MDA is not required. The methodology also included desk research based on Health Department reports of the control activities for lymphatic filariasis during 2003-2016. Among the 934 cases investigated in 2018, there was a 0.64% prevalence of circulating filarial antigen positive, comprising five adults and one 2-year-old child. Six patients aged 39-63 years had filarial disease. Fourteen surveys have already been conducted as control activities, and since 2009, there have been no positive cases. This study showed that the prevalence of antigenemia decreased from 2.97% in 2003 to 0.64% in 2018. Moreover, the transmission of filariasis infection was under control in this area. Our study provides insights into the surveillance phase by identifying areas of low transmission and where MDA is not required. Although we have not identified cases of filarial infection, there is a need to provide services that will provide assist those already affected with morbidity and help reduce and prevent disability.

Filariasis serosurvey, New Caledonia, South Pacific, 2013

Background

Lymphatic filariasis (LF) is a major public health problem in the Pacific. As the global prevalence of infection was not known in New Caledonia (NC), a serosurvey study was conducted by determining the prevalence of circulating filarial antigens, as recommended by the World Health Organization.

Findings

A cross sectional study on a 2 degree stratified sample was carried out from June to November 2013. Inclusion criteria were: individuals aged 2 to 80 y/o, who had been hospitalized or sought medical care for a non-infectious cause and who had been living in NC for more than 6 months. LF antigenic detection was performed using the immunocromatographic BinaxNOW filariasis card test (ICT).

Among the 1,035 individuals tested, 7 were antigenic. The overall LF antigenic prevalence was 0.62% (CI 95% [0.60-0.63]).

All patients were unrelated to each other; none of them presented clinical symptoms of LF.

Four of the 7 ICT positive patients reported having travelled to LF endemic areas, 2 patients had never traveled outside NC and the last one had only traveled in non-endemic areas.

For the 7 ICT positive patients, the research of microfilariae in blood smears and filarial DNA by PCR was negative.

Conclusion

The prevalence of filarial antigenemia in NC is less than 1%, the threshold that defines the filarial endemic areas for WHO. Nevertheless, as two patients who had never travelled outside NC and one who had only travelled to non-endemic areas were antigenic, we cannot conclude that NC is totally free of LF.

Filarial antigenemia and Loa loa night blood microfilaremia in an area without bancroftian filariasis in the Democratic Republic of Congo

Implementation of mass drug administration for lymphatic filariasis (LF) has been delayed in central Africa because of incomplete mapping and coendemic loiasis. We mapped two regions in eastern Democratic Republic of Congo that were suspected to have LF. Night blood samples were collected from 2,724 subjects in 30 villages. Filarial antigenemia rates by card test exceeded 1% in 28 villages (range = 0–14%). Prevalence rates for large sheathed microfilariae (Mf) ranged from 4% to 40%; Mansonella perstans rates ranged from 22% to 98%. Large Mf were exclusively Loa loa by microscopy, and only 1 of 337 samples tested by quantitative polymerase chain reaction (qPCR) was positive for Wuchereria bancrofti DNA. Filarial antigen positivity was strongly associated with high L. loa Mf counts. Periodicity studies revealed atypical patterns, with no significant diurnal periodicity in some individuals. Thus, methods routinely used for LF mapping may not be reliable in areas in central Africa that are highly endemic for loiasis.

Diagnosis of human nematode infections

Many hundreds of millions of people throughout the world are infected by nematodes found in the intestine or tissues with a high prevalence in developing countries. Despite their frequency and morbidity, these infections, which may affect migrants and travelers, remain difficult to diagnosis even in developed countries. This is primarily due to the variety of clinical signs often associated with a lack of highly sensitive and specific diagnostic tools. Parasitological diagnosis is often difficult to achieve and can neither be applied during the pre-patent period nor for parasitic impasses. Serological diagnosis is frequently hampered by a lack of specificity due to cross-reaction with others helminthes. Molecular biology methods still require optimization. The diagnostic approach applied by a clinician of a suspected nematode infection is based on a vast set of data including patient history and way of life, clinical examination, non-specific biological tests and, when available, specific diagnostic tests.

Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood

Global Program to Eliminate Lymphatic Filariasis (GPELF) guidelines call for using filarial antigen testing to identify endemic areas that require mass drug administration (MDA) and for post-MDA surveillance. We compared a new filarial antigen test (the Alere Filariasis Test Strip) with the reference BinaxNOW Filariasis card test that has been used by the GPELF for more than 10 years. Laboratory testing of 227 archived serum or plasma samples showed that the two tests had similar high rates of sensitivity and specificity and > 99% agreement. However, the test strip detected 26.5% more people with filarial antigenemia (124/503 versus 98/503) and had better test result stability than the card test in a field study conducted in a filariasis-endemic area in Liberia. Based on its increased sensitivity and other practical advantages, we believe that the test strip represents a major step forward that will be welcomed by the GPELF and the filariasis research community.

Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment

BACKGROUND

Lymphatic filariasis constitutes a major public health issue in French Polynesia. Diagnosis has been revolutionized with the availability of circulating filarial antigen (CFA) tests which are easy to perform but are costly. Filariasis is responsible for acquired eosinophilia and eosinophil blood count (EBC) is commonly used as a screening tool.

METHODS

We retrospectively analysed all the results of EBCs and CFA tests performed in our laboratory over a 2-year period. We calculated the prevalence of antigenemia for nine different eosinophil cutoffs. We calculated the number of patients detected by CFA testing and the number of estimated CFA-positive patients according to their EBC.

RESULTS

Over a 2-year period, we detected 7503 eosinophilic patients. For an EBC above 500/mm(3), the prevalence of positive CFA was 25·78% and the estimated number of positive CFA patients was 1934. During the same period, as CFA determination is not routinely performed, only 141 patients were detected and treated.

CONCLUSION

Our current strategy against lymphatic filariasis which combines annual mass drug administration, systematic treatment of antigenemic and microfilaraemic patients, and vector control; failed to reach the target of 1% prevalence. Unfortunately, mainly for economical reasons, the antigenemia cannot be determined for all patients. In complement to existing strategy, we propose an additional action based on the treatment of eosinophilic patients in order to reduce the filariasis prevalence in our country.

Predictive value of the eosinophil counts in the biological diagnosis of lymphatic filariasis in French Polynesia

SETTINGS

Lymphatic filariasis is common in many tropical and subtropical areas and is a major public health issue in south Pacific islands. In endemic areas, most infected individuals are asymptomatic but may harbor microfilariae or filarial antigens in their peripheral blood. Microscopy remains the reference diagnostic tool for the identification of microfilariae but is weakly sensitive. The diagnosis of Wuchereria bancrofti infection was dramatically altered by the development of filarial antigen tests, which are easy to perform but expensive for routine use. Lymphatic filariasis is responsible for acquired eosinophilia and blood eosinophil count is commonly used as a screening tool in endemic areas.

METHOD

We retrospectively analyzed all the results of eosinophil counts, antigen and microfilariae detection performed in our laboratory over a 24-month period. We calculated the prevalence of antigenemia for various eosinophilic cut offs.

RESULTS

The prevalence of antigenemia was estimated at 25.78% with eosinophilia defined as a count eosinophilic PMN above 500 per mm(3).

DISCUSSION

Our prevention strategy against lymphatic filariasis is based on annual mass drug administration, vector control, and systematic treatment of antigenemic and microfilaremic patients. Antigenemic and microfilaremic detection cannot be routinely performed because of their cost. Current treatments used for lymphatic filariasis are safe and cheaper than antigenic detection. A possible additional strategy to decrease the prevalence of antigenemia would be the systematic treatment of patients with hypereosinophilia.